TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25634000

Group type: EXPERIMENTAL
Intervention: STEMO care
Number of subjects: 6182

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 6182
Study: 25634207

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 116
Study: 25634486

Group type: EXPERIMENTAL
Intervention: EUS-guided dual through-the-needle imaging (cystoscopy and nCLE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cystoscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nCLE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of cystoscopy and nCLE
Number of subjects: 30
Study: 25634628

Group type: EXPERIMENTAL
Intervention: End-of-life care and communication from ICU staff
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Symptoms of post-traumatic stress disorder, anxiety, and depression in relatives
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Relatives' satisfaction with medical care and communication
Number of subjects: 145
Study: 25634727

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 1

Group type: COMPARATOR
Intervention: MRgx200B;HIFU device
Number of subjects: 1
Study: 25635138

Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg daily)
Number of subjects: 18
Study: 25635704

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 25636046

Group type: EXPERIMENTAL
Intervention: Telotristat etiprate (TE)
Number of subjects: 15
Study: 25637055

Group type: EXPERIMENTAL
Intervention: PAT-SM6 (0.3, 1, 3, and 6 mg/kg)
Number of subjects: 12
Study: 25637377

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 20
Study: 25637379

Group type: EXPERIMENTAL
Intervention: Fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen with granulocyte colony-stimulating factor support followed by weekly paclitaxel
Number of subjects: 11

Group type: COMPARATOR
Intervention: Weekly paclitaxel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: FEC regimen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dose-density regimen with FEC followed by weekly paclitaxel
Number of subjects: 11
Study: 25638754

Group type: EXPERIMENTAL
Intervention: Step-forward randomization with block urn design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimization method with imbalance control threshold and biased coin probability
Number of subjects: 0
Study: 25638805

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 881
Study: 25639506

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m² every 3 weeks with prednisolone 10 mg daily for up to 10 cycles
Number of subjects: 112
Study: 25640580

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 33
Study: 25641086

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity (BRS) decrease
Number of subjects: 425

Group type: COMPARATOR
Intervention: Baroreflex sensitivity (BRS) stable
Number of subjects: 425
Study: 25641401

Group type: EXPERIMENTAL
Intervention: Anal Fistula Plug (AFP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Endorectal Advancement Flap (ERAF)
Number of subjects: 71
Study: 25641532

Group type: EXPERIMENTAL
Intervention: ePRISM consent documents
Number of subjects: 1117
Study: 25641662

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily in 6-week cycles: 4 weeks on treatment, 2 weeks off treatment)
Number of subjects: 1124
Study: 25642145

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg dose
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 12
Study: 25642295

Group type: EXPERIMENTAL
Intervention: Self-referred participants (SRPs)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Actively recruited participants (ARPs)
Number of subjects: 795
Study: 25642392

Group type: EXPERIMENTAL
Intervention: Weekly multimodal MRI follow-up including diffusion tensor imaging (DTI), perfusion imaging, FLAIR, and contrast-enhanced 3D T1-weighted MR.
Number of subjects: 5
Study: 25642774

Group type: EXPERIMENTAL
Intervention: At-risk individuals who progressed to T1D
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-risk subjects
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Evaluation of insulin secretory kinetics
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Blood test measuring unmethylated INS DNA
Number of subjects: 54
Study: 25642832

Group type: EXPERIMENTAL
Intervention: Cluster A (milder disease)
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Cluster B (less systemic inflammation at baseline)
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Cluster C (many comorbidities, evidence of systemic inflammation)
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Cluster D (low FEV1, severe emphysema)
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Cluster E (intermediate for most variables)
Number of subjects: 2164
Study: 25643053

Group type: EXPERIMENTAL
Intervention: MyoSet (MyoGrip, MyoPinch, MoviPlate)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MyoGrip and MyoPinch
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Motor Function Measure
Number of subjects: 53
Study: 25644336

Group type: EXPERIMENTAL
Intervention: Genetic variation in the SCARB1 gene (rs1672879)
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Genetic variation in the SLIT3 gene
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Genetic variation in the DHRS2 gene
Number of subjects: 2581
Study: 25644339

Group type: EXPERIMENTAL
Intervention: Bolus EAA feeding (15 g mixed-EAA as a single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Spread EAA feeding (15 g mixed-EAA in 4 fractions at 45-min intervals)
Number of subjects: 16
Study: 25644488

Group type: EXPERIMENTAL
Intervention: Telescopic extraperitoneal dissection
Number of subjects: 153

Group type: COMPARATOR
Intervention: Balloon dissection
Number of subjects: 153
Study: 25644659

Group type: EXPERIMENTAL
Intervention: 28 mm cryoballoon ablation
Number of subjects: 21
Study: 25644958

Group type: EXPERIMENTAL
Intervention: Chimerism-based immunotherapy (IT) with fast withdrawal of immunosuppression (FWI) and donor lymphocyte infusions (DLI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Full donor chimerism (FDC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chimerism-based immunotherapy (IT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 43
Study: 25645025

Group type: EXPERIMENTAL
Intervention: Influenza A/California/2009 (H1N1) virus, intranasally inoculated at increasing doses (up to 3.5 × 10(6) TCID50)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Influenza A/California/2009 (H1N1) virus, highest dose (3.5 × 10(6) TCID50)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Influenza A/California/2009 (H1N1) virus
Number of subjects: 29
Study: 25645240

Group type: EXPERIMENTAL
Intervention: Tiebreaker algorithm using 3 rapid diagnostic tests (RDTs) in series
Number of subjects: 2620

Group type: COMPARATOR
Intervention: Serial algorithm with 2 RDTs followed by a confirmation test
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Addition of the Orgenics Immunocomb Combfirm® (OIC) confirmation test to either algorithm
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Weakly reactive test lines
Number of subjects: 2620
Study: 25645263

Group type: EXPERIMENTAL
Intervention: Ofatumumab-dexamethasone (O-Dex) regimen
Number of subjects: 33
Study: 25645660

Group type: EXPERIMENTAL
Intervention: IV voriconazole (8.1±2.1 mg/kg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SBECD (129±33 mg/kg/day)
Number of subjects: 10
Study: 25645668

Group type: EXPERIMENTAL
Intervention: Life support
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Comfort measures only
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Uncertain treatment preferences
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Doctor communication about treatment options
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Life-sustaining treatments for more than 7 days
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Satisfaction with nurses
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Satisfaction with decision-making process
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Sense of control over care
Number of subjects: 535
Study: 25645847

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant telaprevir use, inosine triphosphatase genetics, creatinine clearance, weight, and sex
Number of subjects: 0
Study: 25646327

Group type: EXPERIMENTAL
Intervention: Maternal BMI increase (1-kg/m²)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Predicted GWG increase (0.1-kg/wk)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Observed GWG exceeding recommendations
Number of subjects: 826
Study: 25646336

Group type: EXPERIMENTAL
Intervention: 24-h dietary recalls
Number of subjects: 402
Study: 25646793

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 50
Study: 25647532

Group type: EXPERIMENTAL
Intervention: Class C (n=144; 86% sporadic, 9% short, 5% medium-to-long bouts)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Class B (n=174; 93% sporadic, 5% short, 2% medium-to-long bouts)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Class A (n=78; 97% sporadic, 2% short, 1% medium-to-long bouts)
Number of subjects: 396
Study: 25647655

Group type: EXPERIMENTAL
Intervention: Kinesiology majors
Number of subjects: 247

Group type: COMPARATOR
Intervention: Non-kinesiology majors
Number of subjects: 247
Study: 25647685

Group type: EXPERIMENTAL
Intervention: Light intensity physical activity (higher-light intensity)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Light intensity physical activity (lower-light intensity)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (time spent watching television)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (reading and computer use)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Sedentary time (both objectively assessed and self-reported)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (lower sedentary times)
Number of subjects: 1130
Study: 25648230

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with intra-abdominal pressure of 12 mmHg (Group M)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with intra-abdominal pressure of 15 mmHg (Group H)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with intra-abdominal pressure of 9 mmHg (Group L)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intubation
Number of subjects: 40
Study: 25648299

Group type: EXPERIMENTAL
Intervention: Biweekly vinorelbine and oxaliplatin (NVBOX) given every 4 weeks for a maximum of 6 cycles.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Biweekly vinorelbine and oxaliplatin (NVBOX)
Number of subjects: 44
Study: 25648341

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) treatment for approximately 6 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (healthy, nonectatic subjects)
Number of subjects: 129
Study: 25648779

Group type: EXPERIMENTAL
Intervention: Maternal characteristics including genetic, physiologic response to pregnancy, and environmental factors
Number of subjects: 10037

Group type: EXPERIMENTAL
Intervention: Pregnancy ending at <37+0 weeks' gestation
Number of subjects: 10037
Study: 25649171

Group type: EXPERIMENTAL
Intervention: Subvirion H3N2v vaccine (15 µg of hemagglutinin/dose), administered in 2 doses 21 days apart.
Number of subjects: 188
Study: 25649350

Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 90
Study: 25650419

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tear film thickness (TFT) measured with optical coherence tomography (OCT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Correlation between OSDI and TFT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tear film thickness (TFT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Other evaluated signs of DES
Number of subjects: 52
Study: 25650684

Group type: EXPERIMENTAL
Intervention: Working Alliance
Number of subjects: 400
Study: 25651449

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Rate-control drugs
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: VKA use
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Hemorrhagic scores
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Thromboembolic scores
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Overall anticoagulant therapy
Number of subjects: 1072
Study: 25651489

Group type: EXPERIMENTAL
Intervention: Mild disease (native livers and no portal hypertension)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Severe disease (with portal hypertension or post-liver transplant)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Native livers with portal hypertension
Number of subjects: 269

Group type: COMPARATOR
Intervention: Native livers without portal hypertension
Number of subjects: 269
Study: 25651730

Group type: EXPERIMENTAL
Intervention: UMSC transfusion
Number of subjects: 18
Study: 25651830

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m²) + Dexamethasone (20 mg for 2 days with each Bz dose)
Number of subjects: 100
Study: 25652454

Group type: EXPERIMENTAL
Intervention: PF-05212384, administered intravenously once weekly at a maximum-tolerated dose (MTD) of 154 mg
Number of subjects: 77
Study: 25653396

Group type: EXPERIMENTAL
Intervention: Abbott RealTime HCV RNA assay
Number of subjects: 663

Group type: COMPARATOR
Intervention: High Pure System
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Abbott RealTime HCV RNA assay (<12 IU/ml)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: High Pure System or Abbott RealTime (<12 IU/ml)
Number of subjects: 663
Study: 25653574

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fondaparinux 1.5 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Edoxaban 30 mg
Number of subjects: 50
Study: 25653826

Group type: EXPERIMENTAL
Intervention: Quetiapine immediate-release (IR)
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (XR)
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Quetiapine XR
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: Switch to XR
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Continuous IR
Number of subjects: 1761
Study: 25654354

Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg (Control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg (Experimental)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rifampin 25 mg/kg (Experimental)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rifampin 30 mg/kg (Experimental)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rifampin 35 mg/kg (Experimental)
Number of subjects: 75
Study: 25654540

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) parameters
Number of subjects: 100
Study: 25654812

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60-mg single dose
Number of subjects: 36
Study: 25655063

Group type: EXPERIMENTAL
Intervention: Baseline haemodynamic severity (mean pressure gradient - MPG)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Baseline anatomic severity (degree of aortic valve calcification - AVC)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Correlation between annualised haemodynamic and anatomic progression rates
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Baseline MPG and AVC as independent determinants of AVC progression
Number of subjects: 149
Study: 25655379

Group type: EXPERIMENTAL
Intervention: Siltuximab 5.5 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Siltuximab 11.0 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Siltuximab (both doses)
Number of subjects: 9
Study: 25655456

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25655621

Group type: EXPERIMENTAL
Intervention: Numeta
Number of subjects: 374

Group type: COMPARATOR
Intervention: Individualized PN
Number of subjects: 374
Study: 25656734

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Non-vaccinated patients
Number of subjects: 497
Study: 25658479

Group type: EXPERIMENTAL
Intervention: Inhibition of urge to eat (appetite control)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Passive viewing of food pictures
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Imagined eating of foods
Number of subjects: 41
Study: 25659285

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg once daily) plus Ribavirin (1000 mg or 1200 mg twice daily for 24 weeks or 12 weeks for treatment-naive genotype-2 patients)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus Ribavirin
Number of subjects: 275
Study: 25659436

Group type: EXPERIMENTAL
Intervention: Patients with clinically relevant depressive symptoms (CRDS) defined by a BDI-score ≥18
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Patients with CRDS
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Patients with ischemic stroke or TIA (n = 1,832)
Number of subjects: 2007
Study: 25659911

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (hepatic study)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg (renal study)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Canagliflozin (renal study)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Canagliflozin (both studies)
Number of subjects: 16
Study: 25660004

Group type: EXPERIMENTAL
Intervention: Transition preparation program
Number of subjects: 10
Study: 25661570

Group type: EXPERIMENTAL
Intervention: Manual compression (MC) performed by paramedics
Number of subjects: 3503

Group type: COMPARATOR
Intervention: Manual compression (MC) performed by physicians
Number of subjects: 3503

Group type: COMPARATOR
Intervention: Vascular closure devices (VCDs)
Number of subjects: 3503
Study: 25663351

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 25664185

Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir 300/100 mg qd
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir 400/100 mg qd
Number of subjects: 44
Study: 25664404

Group type: EXPERIMENTAL
Intervention: Self-injection with the autoinjector (50 mg subcutaneous golimumab once monthly for 6 months)
Number of subjects: 3280

Group type: EXPERIMENTAL
Intervention: Self-injection with the autoinjector
Number of subjects: 3280
Study: 25664534

Group type: COMPARATOR
Intervention: Blue dye alone
Number of subjects: 689

Group type: COMPARATOR
Intervention: Radiolabeled colloid
Number of subjects: 689

Group type: COMPARATOR
Intervention: Dual mapping agents (radiolabeled colloid and blue dye)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Mapping technique (blue dye vs radiolabeled colloid +/- blue dye)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Overall SLN identification
Number of subjects: 689
Study: 25664604

Group type: EXPERIMENTAL
Intervention: Oral octreotide capsules (OOCs) 40 mg/d, escalated to 60 mg/d and then 80 mg/d for 7 months
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Oral octreotide capsules (OOCs)
Number of subjects: 155
Study: 25664714

Group type: EXPERIMENTAL
Intervention: Synthetic bioabsorbable anal fistula plug
Number of subjects: 93
Study: 25664865

Group type: EXPERIMENTAL
Intervention: Intermediate Care Unit (IMCU) present
Number of subjects: 5834

Group type: COMPARATOR
Intervention: No Intermediate Care Unit (IMCU)
Number of subjects: 5834
Study: 25665007

Group type: EXPERIMENTAL
Intervention: Cisplatin treatment with ACYP2 risk variant (rs1872328)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group of 68 similarly treated children
Number of subjects: 238
Study: 25665464

Group type: EXPERIMENTAL
Intervention: SB-743921 with G-CSF (9 mg/m² MTD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: SB-743921 without G-CSF (6 mg/m² MTD)
Number of subjects: 68
Study: 25665799

Group type: EXPERIMENTAL
Intervention: Teaching intervention after DR1
Number of subjects: 14

Group type: COMPARATOR
Intervention: Contouring dummy run (DR1)
Number of subjects: 14
Study: 25665816

Group type: COMPARATOR
Intervention: Type 1 diabetes with inadequate glycemic control (T1D-I)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Type 1 diabetes with adequate glycemic control (T1D-A)
Number of subjects: 18
Study: 25666151

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 18
Study: 25666192

Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of ≤53 days (n=19)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of 54-82 days (n=20)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of 83-110 days (n=20)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: HCC with a doubling time of ≥111 days (n=19)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Five-gene transcriptomic hepatic signature
Number of subjects: 132
Study: 25666343

Group type: EXPERIMENTAL
Intervention: Cervical elastography measurement using HI-RTE imaging in the first trimester
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cervical elastography index threshold value ≤0.38
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cervical length ≤36mm combined with elasticity index ≤0.38
Number of subjects: 72
Study: 25666356

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 14